Skip to content

Bone Marrow Hematopoietic Abnormalities and the Underlying Mechanisms in Sepsis

Bone Marrow Hematopoietic Abnormalities and the Underlying Mechanisms in Sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105873
Enrollment
Unknown
Registered
2025-07-14
Start date
2025-07-15
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

Sepsis group:None
Healthy control group:None

Sponsors

Army Medical Center of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Sepsis patient: meet the diagnostic criteria of Sepsis-3.0, i.e., infection + Sequential Organ Failure Assessment (SOFA) score = 2 points;Aged 18-80 years;Signed the informed consent form. 2.General infection patients: Unexplained fever (body temperature >37.3°C), with positive results in clinical tests showing microbial culture positivity or viral antigen/IgM antibody detection positivity, but without multi-organ dysfunction (i.e., SOFA score <2);Aged 18-80 years;Signed the informed consent form. 3.Healthy controls: aed 18-80 years;with negative test results for infection, no history of chronic diseases, and diagnosed by the hematology department as having iron-deficiency anemia or thrombocytopenia that does not affect bone marrow hematopoiesis;Signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Sepsis patients: with concurrent malignant tumors, autoimmune diseases, or severe hematological disorders; have received immunosuppressive therapy or had a history of blood transfusion within the recent 3 months; with severe hepatic or renal dysfunction; Pregnant or lactating women. 2.General infection patients: with manifestations of sepsis or progression to sepsis(SOFA=2); with concurrent malignant tumors, autoimmune diseases, or severe hematological disorders; have received immunosuppressive therapy or had a history of blood transfusion within the recent 3 months; with severe hepatic or renal dysfunction; Pregnant or lactating women. 3.Healthy controls: with a history of infection within the recent 1 month(microbial culture positivity or viral antigen/IgM antibody detection positivity); a history of chronic diseases, ongoing use of drugs affecting the immune system, a history of blood transfusion; pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Differences in composition, function, and gene expression of immune cells within the same population;

Secondary

MeasureTime frame
ICU stay;SOFA scores;

Countries

China

Contacts

Public ContactZeng Ling

Army Medical Center of PLA

516161006@qq.com+86 23 68757512

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026